As patents on these drugs expire, generic manufacturers can produce and market bioequivalent versions at a lower cost. This process, known as the "patent cliff," creates opportunities for generic drug manufacturers to capture market share from brand-name drugs. https://www.imarcgroup.com/china-generic-drug-market